Sigrun Metz

Title: Sigrun Metz: Innovator in Immunoassay Technologies

Introduction

Sigrun Metz is a prominent inventor based in Munich, Germany. She has made significant contributions to the field of immunoassays, particularly in the development of protease inhibitor conjugates and antibodies. With a total of 3 patents to her name, her work has had a substantial impact on medical diagnostics.

Latest Patents

Sigrun Metz's latest patents focus on activated haptens that are useful for generating immunogens related to HIV protease inhibitors. These patents include innovations for producing antibodies to HIV protease inhibitors and developing antibodies and labeled conjugates for immunoassays targeting the HIV protease inhibitor saquinavir. The novel haptens she has developed feature an activated functionality at the central, non-terminal hydroxyl group. Additionally, her patents describe monoclonal antibodies specific for saquinavir, which exhibit less than 10% cross-reactivity with other protease inhibitors such as lopinavir, nelfinavir, amprenavir, ritonavir, and indinavir. A murine hybridoma producing these specific antibodies is also part of her innovative work.

Career Highlights

Sigrun Metz is currently employed at Roche Diagnostics Operations, Inc., where she continues to advance her research in immunoassay technologies. Her expertise and innovative approach have positioned her as a key figure in her field.

Collaborations

Throughout her career, Sigrun has collaborated with notable colleagues, including Gerald F. Sigler and Raymond Hui. These partnerships have further enhanced her research and development efforts.

Conclusion

Sigrun Metz is a trailblazer in the field of immunoassays, with a focus on HIV protease inhibitors. Her innovative patents and collaborations reflect her commitment to advancing medical diagnostics. Her contributions continue to shape the landscape of immunoassay technologies.